Press & Media Kit

Press & Media Kit

Approved boilerplate, executive bios, product fact sheets, brand assets, and media-ready language for Electrome Corporation and ActiPatch®.

For Press

Press Releases

Official Electrome announcements and recent press coverage.

View all

Electrome Newsroom · 2026-05-08

Electrome launches the bioelectric medicine platform

Electrome Corporation publicly introduces electrome.com as the corporate face of its bioelectric medicine platform, anchored by FDA-cleared PSWT and ActiPatch®.

For Editors

Approved Company Boilerplate

Use verbatim when referencing Electrome Corporation in editorial coverage.

Short

The bioelectric medicine platform.

Electrome is a bioelectric medicine company. We translate decades of peer-reviewed bioelectric science into FDA-cleared therapies and AI guided care, starting with chronic pain and inflammation.

Long

Electrome Corporation

Electrome builds a vertically integrated bioelectric medicine platform: regulated devices, an AI care layer, and a data-grade clinical pipeline. Our first commercial product, ActiPatch®, is an FDA 510(k) cleared Pulsed Shortwave Therapy (PSWT) device for musculoskeletal pain. Beyond pain, our pipeline targets recovery, sleep, women's health, and other high-burden indications where bioelectric signaling is supported by published clinical evidence.

Products & Programs

Product Fact Sheets

Approved descriptions for the ActiPatch™ product line and Electrome programs.

Fact Sheet

ActiPatch® (FDA 510(k) cleared)

ActiPatch® is an FDA 510(k) cleared (K192234), over-the-counter, drug-free wearable delivering 27.12 MHz pulsed shortwave therapy for adjunctive treatment of musculoskeletal pain. Each device provides 720 therapy hours.

Fact Sheet

ActiPatch®

ActiPatch® is an FDA 510(k) cleared (K192234), over-the-counter, drug-free wearable delivering 27.12 MHz pulsed shortwave therapy for adjunctive treatment of musculoskeletal pain. Each device provides 720 therapy hours.

Fact Sheet

Provider Program

Clinician-directed education and workflow information for qualified providers.

Fact Sheet

Retailer Program

ActiPatch® is an FDA 510(k) cleared (K192234), over-the-counter, drug-free wearable delivering 27.12 MHz pulsed shortwave therapy for adjunctive treatment of musculoskeletal pain. Each device provides 720 therapy hours.

Fact Sheet

Electrome Corporation — Investor Overview

Electrome is a bioelectric medicine company. We translate decades of peer-reviewed bioelectric science into FDA-cleared therapies and AI guided care, starting with chronic pain and inflammation.

Leadership

Executive Bios

Approved bios for Electrome leadership, advisors, and clinical board.

Erik A. Nilsen, PhD

Erik A. Nilsen, PhD

Co-founder, Chief Executive Officer & Chief Technical Officer

Erik is a physicist and entrepreneur with advanced degrees in electrical engineering and mathematics who has spent 25+ years building bioelectric recording, control, and stimulation systems, securing multiple patents, contributing to multiple successful exits, and leading work across NIST ATP, NIH, and DARPA programs. As CEO, he sets the company's strategic direction and aligns its science, technology, and commercial roadmap around a single goal, making FDA-cleared bioelectric therapy broadly accessible. He brings the rare combination of deep technical fluency and the disciplined execution and capital formation needed to build Electrome into a leader in bioelectric medicine.

Nev Zubcevik, D.O.

Nev Zubcevik, D.O.

Co-founder & Chief Medical Officer

Dr. Nev Zubcevik is a board-certified physician and former Harvard Medical School faculty member and Medical Director at Spaulding Rehabilitation Hospital, with deep expertise in musculoskeletal medicine, traumatic brain injury, concussion, and non-pharmacologic pain management. She is also a prolific inventor and researcher whose work spans bioelectric signaling, regenerative medicine, and chronic Lyme disease, including the LymeCure research collaboration with Tulane University, alongside peer-reviewed research on non-opioid recovery. At Electrome she directs clinical strategy, evidence generation, and the integration of bioelectric therapy into mainstream care pathways.

Danny Rubenstein

Danny Rubenstein

Chief Commercialization Officer

Danny Rubenstein is a commercial operator and strategic advisor with 40+ years across consumer products, food, and emerging businesses. He has held CEO, COO, and CFO roles, was an original partner in Naked Juice and has served as member of operating leadership teams with several startup and early stage companies. Danny applies a regenerative, whole systems approach, advising founders and leadership teams on strategy, growth and developing organizational capacity. At Electrome he leads commercialization strategy, channel development, and revenue execution.

Shari O'Connor, PharmD, MBA

Shari O'Connor, PharmD, MBA

Scientific Advisor, Clinical Marketing & Sales Development

Shari O'Connor is a neuroimmunology expert with 30+ years advancing brain and immune-system therapies, with board-level credentials in Neurology, Immunology, Nutrition, and Pharmacogenomics. Her published research spans encephalopathy, brain trauma, and immune-mediated neurological disease, and she has advised programs translating neuroscience research into pharmacy practice and clinical care. At Electrome she leads clinical marketing and sales development, translating the evidence base into the form clinicians, channel partners, and payer audiences evaluate and buy on. In a category where adoption is won on clinical credibility rather than promotion, her scientific standing is itself the commercial asset.

Samir S. Awad, MD

Samir S. Awad, MD

Medical Director

Dr. Samir S. Awad is Chief of Surgery and Operative Care Line Executive at the Michael E. DeBakey VA Medical Center in Houston, and Professor of Surgery and Vice-Chair for Surgical Quality and Safety at Baylor College of Medicine. A bioengineering graduate of Penn with surgical critical-care training at Michigan, he leads investigator-initiated clinical research across pain, wound healing, edema, and bioelectric therapeutics. At Electrome he serves as Medical Director, guiding FDA strategy and clinical evidence generation across the platform.

Wanni Davis, PhD, MBA

Wanni Davis, PhD, MBA

Licensing Advisor

Wanni Davis is a biotech strategist with 15+ years spanning translational science, venture development, and commercialization. As former Director of Industry Partnerships at Harvard-affiliated hospitals, she built and negotiated the industry alliances that move academic science out of the lab and into commercial development. At Electrome she serves as Licensing Advisor, leading partnerships, business development, and alliance operations across life sciences and biopharma, including partner agreements and the licensing pathway around Electrome's patent-pending portfolio.

Editorial Standards

Approved Language for Media Use

Copy-safe language pulled verbatim from Electrome's source-of-truth entities.

What Electrome does

Electrome is a bioelectric medicine company. We translate decades of peer-reviewed bioelectric science into FDA-cleared therapies and AI guided care, starting with chronic pain and inflammation.

What ActiPatch® is

ActiPatch® is an FDA 510(k) cleared (K192234), over-the-counter, drug-free wearable delivering 27.12 MHz pulsed shortwave therapy for adjunctive treatment of musculoskeletal pain. Each device provides 720 therapy hours.

Bioelectric medicine (PSWT)

PSWT is a nonthermal, noncontact form of pulsed electromagnetic field (PEMF) therapy operating at 27.12 MHz. Unlike TENS, it is delivered by a self-contained wearable—no electrode pads or lead wires to manage. Designed to operate without perceptible heat or tingling from the device.

FDA-cleared device, ActiPatch®

ActiPatch® is an FDA 510(k) cleared (K192234), over-the-counter, drug-free wearable delivering 27.12 MHz pulsed shortwave therapy for adjunctive treatment of musculoskeletal pain. Each device provides 720 therapy hours.

Regulatory status: FDA 510(k) cleared.

Non-drug pain relief

PSWT is supported by decades of peer-reviewed research, including two double-blind, placebo/sham-controlled trials: a knee osteoarthritis RCT (Bagnato et al., Rheumatology 2016) reporting significant pain and function gains at one month, with 26% of patients stopping analgesics entirely and no adverse events; and a plantar fasciitis trial (Brook et al., J Foot Ankle Surg 2012) showing a significant reduction in first-step morning heel pain. A UK real-world registry of 5,000+ patients (Rawe & Kotak, Pain Management 2015) additionally reported, on a self-reported basis, a 57% mean pain reduction among the 65% who responded, with 93% still relieved at three months.

Downloads

Asset Library

Approved logos, product imagery, executive headshots, and documents. Items marked “Available by request” are released to credentialed press through the press contact flow.

Product Imagery

ActiPatch® packaging and therapy device imagery.

Documents

Approved Electrome documents available for the press.

Sell Sheets

ActiPatch® product sell sheets are released to credentialed press by request (source PDFs are gated behind the investor-documents portal).

Media Contact

Press & Communications, Electrome Corporation

bioelectrictherapy@electrome.com — response within 1–2 business days for interviews, statements, and asset requests.